|Bid||28.63 x 2200|
|Ask||29.99 x 1000|
|Day's Range||29.59 - 30.56|
|52 Week Range||17.80 - 31.78|
|Beta (5Y Monthly)||2.64|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020 - Mar 2, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||46.71|
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced in vivo proof-of-concept data supporting the development of EDIT-301 as a potentially best-in-class, durable medicine to treat sickle cell disease and beta-thalassemia. EDIT-301 is the first experimental medicine in development using Cas12a (formerly known as Cpf1). The Company reported these data today at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH) in Orlando, Fla.
Vertex (VRTX) and partner CRISPR Therapeutics announce positive early data from two studies on gene-editing drug CTX001 for the treatment of beta-thalassemia and sickle cell disease.
CRISPR Therapeutics and Vertex Pharmaceuticals released the first data from their early-stage trial testing the safety and effectiveness of a potential cure for the genetic blood disorders sickle cell disease and beta thalassemia.
Editas (EDIT) delivered earnings and revenue surprises of 9.59% and -6.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Amended Celgene collaboration to focus on engineered alpha-beta T cell medicines with a $70 million payment to Editas Medicine Appointed Judith R. Abrams, M.D., as Chief.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced an amended collaboration with Celgene Corporation (CELG) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. Under the terms of the amended agreement, Editas Medicine will receive a payment of $70 million. “Celgene is the leader in advancing innovative cell medicines to treat blood cancers, and we are excited to expand our productive working relationship with the Celgene team as we increase our commitment to advancing gene-edited cell medicines in oncology and beyond,” said Charles Albright, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine.
CAMBRIDGE, Mass., Nov. 05, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on.
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced that it named Judith R. Abrams, M.D., as the Company’s Chief Medical Officer, effective immediately. Dr. Abrams is a leading drug development clinician who has brought multiple medicines from clinical stage development to regulatory approval. “We are delighted to have Judith join our leadership at this important juncture for the Company with the recent initiation of the Phase 1/2 Brilliance trial of EDIT-101 (AGN-151587) for the treatment of patients with Leber congenital amaurosis 10 (LCA10),” said Cynthia Collins, President and Chief Executive Officer, Editas Medicine.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Editas Medicine, Inc. (EDIT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Editas (EDIT) and privately held Asklepios BioPharmaceutical will collaborate on exploring in vivo delivery of genome editing medicines to treat neurological diseases.
CAMBRIDGE, Mass. and RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, and Asklepios BioPharmaceutical,.
Editas Medicine, Inc. (EDIT), a leading genome editing company, and MaxCyte, Inc., the global cell-based therapies and life sciences company, today announced a new clinical and commercial license agreement. Editas Medicine will use MaxCyte’s Flow Electroporation® technology and ExPERT™ instruments for the advancement of engineered cell medicines, including EDIT-301, an experimental CRISPR medicine designed to durably treat sickle cell disease and beta-thalassemia. Under the terms of the agreement, Editas Medicine obtains non-exclusive clinical and commercial use rights to MaxCyte's cell engineering platform to develop up to five therapies including four immuno-oncology therapies, and in return MaxCyte will receive development and approval milestones and sales-based payments in addition to other licensing fees.
CAMBRIDGE, Mass., Oct. 01, 2019 -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that management will participate in the following.